Pfizer Inc. (NYSE:PFE)‘s stock had its “buy” rating reiterated by equities researchers at BMO Capital Markets in a research note issued on Thursday, September 14th. They currently have a $37.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 3.64% from the stock’s current price.
A number of other equities analysts have also issued reports on PFE. ValuEngine lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Morgan Stanley reiterated a “neutral” rating and set a $35.00 price target (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Jefferies Group LLC restated a “neutral” rating and issued a $34.00 price objective on shares of Pfizer in a research note on Friday, June 16th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Finally, Cowen and Company set a $43.00 price target on Pfizer and gave the company a “buy” rating in a research report on Monday, July 10th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average price target of $38.04.
Pfizer (NYSE PFE) opened at 35.70 on Thursday. Pfizer has a one year low of $29.83 and a one year high of $36.21. The company has a market capitalization of $212.32 billion, a price-to-earnings ratio of 26.12 and a beta of 1.00. The firm has a 50-day moving average of $33.78 and a 200 day moving average of $33.53.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 21.10% and a net margin of 23.85%. The business’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.64 earnings per share. Equities research analysts predict that Pfizer will post $2.56 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “BMO Capital Markets Reiterates Buy Rating for Pfizer Inc. (NYSE:PFE)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/02/pfizer-inc-pfe-earns-buy-rating-from-bmo-capital-markets.html.
In other news, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at $19,730,812. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last quarter, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the company. Asset Planning Services Ltd. boosted its stake in Pfizer by 4.9% in the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new stake in Pfizer in the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer during the 2nd quarter valued at about $103,000. D. Scott Neal Inc. increased its stake in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the last quarter. Finally, Orrstown Financial Services Inc. lifted its holdings in shares of Pfizer by 23.0% during the 1st quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 612 shares during the period. 69.00% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.